Botox for TMJ Dysfunction

Temporomandibular disorder (TMD) is a nonspecific term used to describe orthopedic and myofascial disorders that affect the TMJ. The prevalence of TMD is between 30% and 44%, with up to 25% of the population seeking professional care for TMD. Symptoms are commonly related to pain surrounding the joint and may include headache, periauricular pain, neck pain, decreased jaw excursion, jaw locking, and noise at the joint with movement. In general, TMD is divided into myofascial TMD or arthrogenic TMD. Myofascial TMD is associated with the pain from hyperfunctioning muscles of mastication leading to chronic myositis. In contrast, arthrogenic TMD is associated intracapsular pathology with pain at the level of the joint itself.

Anatomy of temporomandibular joint (TMJ)

The temporomandibular joint (TMJ) is a hinged synovial joint that connects the mandible to the temporal bone at the skull base, and the posterior border of the TMJ is the anterior border of the external auditory canal. The TMJ is one of the few synovial joints with an articular disc and it functions as both a hinge joint and a sliding joint. It is therefore classified as a ginglymoarthrodial joint. Adduction of the mandible, or mouth closing, is performed by the actions of the masseter, temporalis, and medial pterygoid muscles. Abduction, or mouth opening, is performed by the lateral pterygoids and digastric musculature. The lateral deviation occurs by the action of the contralateral lateral pterygoid muscles, and protrusion of the mandible occurs when right and left lateral pterygoid muscles contract simultaneously.

TMJ Dysfunction

The diagnosis of TMJ dysfunction is based on history and physical exam findings. Patients should be asked about nighttime bruxism, jaw soreness, morning headaches, use of mouth orthodonitics, or history of trauma. Questions regarding the patient’s personal habits and diet should be evaluated to reduce behaviors that may place additional stress on the TMJ, like frequent gum chewing. Symptoms of depression, anxiety or recent stressors should also be assessed as these conditions often lead to unconsciously clench.

Signs and symptoms of TMD may include joint or muscular pain with or without jaw opening/closing, limited jaw movement, cracking or popping sounds at the TMJ with movement, or headaches. Patients often present with otalgia, ear fullness or tinnitus which is referred from the anterior external auditory canal and is a shared border with the posterior TMJ. In addition, otalgia may be referred from muscles of mastication as some middle ear muscles (tensor tympani and tensor palatini) are also innervated by the trigeminal nerve. Some patients with TMD have complained of unilateral and boring orbital or periorbital pain, which could be neurogenic or due to hyperfunctioning temporalis muscles often present with otalgia, ear fullness or tinnitus which is referred from the anterior external auditory canal, and is a shared border with the posterior TMJ.

Botulinum toxin

The first indication that BoNT could be useful for treating pain was observed from anecdotal reports of patients treated for hyperfunctional facial lines who reported reduced frequency and severity of headache. Soon thereafter, the pain-relieving effect of BoNT was reported during the treatment of oromandibular dystonia and cervical dystonia. Today, BoNT is used for pain relief in numerous conditions including tension headaches, migraine headaches, post-herpetic neuralgia and myofacial TMD.

Mechanism of action

BoNT is a 150-Kilodalton exotoxin produced from clostridium botulinum, whose action is mediated through the cleavage of docking proteins that are responsible for membrane fusion of pre-synaptic vesicles. Type A bolulinum toxin (BoNT-A) cleaves the membrane associated protein “synaptosomal-associated protein 25” (SNAP-25) which is a member of the “soluble N-ethylmaleimide sensitive factor attachment protein receptor protein (SNARE). Type B botulinum toxin (BoNT-B) cleaves synaptobravin, which is part of the vesicular-associated membrane protein (VAMP). Cleavage of these docking proteins leads to muscle weakens by inhibition of acetylcholine (Ach) release at the neuromuscular junction.

Botulinum Toxin Injection for TMJ dysfunction

The most commonly affected muscles are the temporalis muscle, masseter muscle and lateral pterigoid muscles. The temporalis muscle and masseter muscle are almost always involved and usually manifest as direct muscle pain. Lateral pterygoids involvement usually manifests as buccal pain, lateral jaw deviation or bruxism.

The injections are performed under real-time ultrasound guidance. We typically use a concentration of 2.5–5.0 units per 0.1 mL of Botox with a starting dose of 10–25 units for each temporalis muscle, 25–50 units to the masseter muscles and 7.5–10 units to the lateral pterygoids. Subsequent doses are individualized and are based on the patients’ response. Botox diffuses to about 1 cm at each injection site, and affected areas may be left untreated if an inadequate number of sites are infiltrated within a single muscle group. To avoid an incomplete response, we advocate using lower concentrations at multiple sites with larger injection volumes.

Approximately 3-4 weeks after the initial injection, patients are reevaluated for any adverse effects and/or suboptimal responses. Some patients may require a booster injection at that time. Additional BoNT injections are directed by the patients’ history and clinical examination, and pain diaries are a useful guide to help in patient directed therapy. It may take several weeks before patients experience the maximum pain relief from BoNT. Although the typical duration of efficacy is 12 weeks, we have noted tremendous variability among patients with respect to optimal dosing frequency. Some patients experience relief well beyond the predicted pharmacokinetic duration of the drug supporting the possibility that BoNT does not strictly act at the periphery and may be involved in neuromodulation at the level of the central nervous system. It is important to note that an individual patient’s response to toxin may change over time, which further supports the importance of patient-directed dosing.

Complications of botox injections

BoNT injection for TMD is administered in relatively small doses and way below the estimated lethal dose of approximately 3000 units. Because of the relative low dosing profile, adverse effects are uncommon and often mild. Difficulty chewing is the most common adverse effect, which results from local muscle weakness and is usually dose dependent. Muscle atrophy may result in cosmetic alterations and is another risk of the procedure. Higher volume of BoNT increased the risk of diffusion of toxin to nearby areas which may cause brow ptosis, blepharoptosis or diplopia if the temporalis muscle is injected  too close to the orbit. Facial asymmetry may result if the masseter muscle is injected too close to the zygomaticus major.  Dry mouth may occur if BoNT is injected into the parotid gland. Flu-like syndromes rarely occur and are usually of brief duration. In addition, with any injection there is an inherent risk associated with a needle puncture, such as bruising, local tenderness, infection and nerve injury.

Contraindications to Botox injections

Contraindications to BoNT use include a known allergy to BoNT, active inflammation or infection at the proposed injection site, pregnancy, breast-feeding, or chronic degenerative neuromuscular disorders like amyotrophic lateral sclerosis, myasthenia gravis, Lambert-Eaton syndrome, muscular dystrophy or multiple sclerosis. Patients taking aminoglycoside antibiotics should not receive BoNT injections because this class of antibiotics may interfere with the neuromuscular transmission of toxin and potentiate the effect of BoNT.

Efficacy of botox injections in TMJ dysfunction

Numerous studies have shown that BoNT provides long-term relief of myofascial TMD by decreasing the intensity, frequency, and duration of recurrent episodes. Freund et al reported on 46 patients with TMD treated with 150 units of BoNT-A to the masseters and temporalis muscles. They found significant reductions in their subjective and objective pain scores, and all patients with restricted mouth opening had some degree of improved range of motion. They also reported successful treatment various conditions that fall under the general category of TMD such as bruxism and clenching, oromandibular dystonias, trismus, masseter and temporalis hypertrophy, and headaches.

In a multicenter randomized double-blind, placebo-controlled fixed-dose study (50 units Botox to each masseter muscle and 25 units Botox to each temporalis muscle), reduction of subjective pain and tenderness to palpation was greatest at eight weeks following injections. The authors of this study also noted a decrease in the average daily use of pain medication over the 16-week duration of this study.

Summary

Temporomandibular disorder is a common cause of chronic facial pain and is known to interfere with personal relations, professional duties, and overall quality of life. Appropriate diagnosis allows physicians to identify the disorder and initiate an effective therapeutic plan. Botulinum toxin can provide long-term relief of TMD by reducing the intensity, frequency, and duration of recurrent episodes. Adverse effects from BoNT injections are uncommon, mild and transient making it an attractive option for adjunctive therapy for myofascial TMD in patients who have failed initial conservative therapy and systemic pharmacotherapy.

Have a question? Or would like to book in with us?

Get in Touch

Common Conditions
that we Treat Everyday

View All Conditions

Latest from the Blog

Posted 07 Feb, 2019

Stellate Ganglion Block a Potential Lifesaver in Severe PTSD

Case reports are mounting of immediate, durable, and significant relief of severe refractory symptoms of posttraumatic stress disorder (PTSD), according to an anesthesiologist who has seen the benefits firsthand. Stellate ganglion blockade (SGB) “seems to significantly improve PTSD symptoms as well as significant...
Posted 25 Jan, 2019

CGRP Antagonists: A new era for migraine treatment

Migraine is a common medical condition, affecting as many as 37 million people in the US. It is considered a systemic illness, not just a headache. Recent research has demonstrated that changes may begin to occur in the brain as long as 24 hours before migraine symptoms begin. Many patients have a severe throbbing head...